IP Library Granted Patent US 9,499,811
Granted Patent B2
US 9,499,811 · App. 14/190,747 · Granted Nov 22, 2016

Ligation enhancement

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,499,811
App. No.
14/190,747
Granted
Nov 22, 2016
Kind
B2
Abstract

Compositions and methods are provided for enhancing enzymatic ligation between nucleic acid fragments that relies on one or more small molecule enhancers having a size of less than 1000 daltons. For example, enhancement of ligation efficiencies are observed for double-stranded nucleic acid fragments that are blunt-ended, have a single nucleotide overhang at the ligation end, or have staggered ends compared to ligation under similar conditions in the absence of the one or more small molecule ligation enhancer. The use of small molecule enhancers for ligating nucleic acids results in an increased number of transformed host cells after transformation with the ligated molecules. This enhancement can be observed with chemically transformed host cells and with host cells transformed by electroporation.

Claims (8)

1. A method of enhancing ligation between nucleic acid fragments, the method comprising:

(a) mixing a composition comprising T4 DNA ligase and a ligase reaction buffer comprising one or more small molecule diol ligation enhancers having a molecular weight of less than 500 daltons at a concentration of 1%-50% v/v, with a plurality of nucleic acid fragments in a ligation buffer; and

(b) permitting ligation wherein the efficiency of ligation is enhanced by at least 25% compared to the efficiency of a ligation in the absence of the small molecule enhancer.

2. A method according to claim 1 , wherein ligation is intramolecular.

3. A method according to claim 1 , wherein ligation is intermolecular.

4. A method according to claim 1 , wherein the plurality of nucleic acid fragments are double-stranded DNA with blunt ends, single-base overhangs or staggered ends.

5. A method according to claim 1 , wherein the efficiency of ligation is enhanced by at least 4-fold as determined by electroporation of host cell.

6. The method of claim 1 , wherein the one or more small molecule diol ligation enhancers are selected from the group consisting of 1,2-propanediol (1,2-PrD), 1,3-propanediol (1,3-PrD), 2-methyl-1,3-propanediol, 2,2-dimethyl-1,3-propanediol, 1,3-butanediol, 1,4-butanediol, 1,5-pentanediol, 1,6-hexanediol, 1,9-nonanediol, 1,12-dodecanediol, 1,3-butylethylpropanediol, methylpropanediol, and methylpentanediols.

Assignments (2)
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Sep 27, 2023
From: NEW ENGLAND BIOLABS, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 065044/0729 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2016
From: KUCERA, REBECCA; EVANS, THOMAS C.
To: NEW ENGLAND BIOLABS, INC.
Reel/Frame 040013/0926 →